Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04146909
Other study ID # 2000025731
Secondary ID 1R21HD100751-01
Status Terminated
Phase N/A
First received
Last updated
Start date November 17, 2020
Est. completion date November 28, 2022

Study information

Verified date February 2024
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This purpose of this study is to investigate whether lactation improves insulin sensitivity and increases lipolysis in women.


Description:

There are two aims that this research will address. In Aim 1, the research question is "Does lactation improve insulin sensitivity and increase lipolysis in women?" In this Aim, researchers will assess whether lactation amongst women with a history of gestational diabetes mellitus (GDM) will improve whole body insulin sensitivity as well as increase whole body lipid turnover by using hyperinsulinemic-euglycemic clamps combined with [6,6-2H]-glucose and [2H5]-glycerol infusions. These stable, non-radiating isotopes have been used extensively and safely to study the mechanisms of insulin resistance amongst non-pregnant as well as pregnant humans; however, these techniques have not previously been applied to the study of insulin sensitivity during lactation. Therefore, the goals will be two-fold: 1) to determine whether lactation induces similar changes in insulin sensitivity in humans as in mice and 2) to pilot the feasibility of performing larger, more detailed metabolic studies in this population of women post-partum. The second aim (Aim 2) will use a retrospective chart review of women with a history of GDM who had an oral glucose tolerance test (OGTT) 6-8 weeks post-partum as part of standard of care. The focus of this protocol registration will be Aim 1.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date November 28, 2022
Est. primary completion date November 28, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - A history of GDM (as defined as the American Diabetes Association criteria) - Delivered a singleton, live birth at = 35 weeks gestation within the past 18 months - HbA1C < 6.5% at time of screening - Delivery within the past 18 months - Breast Feed Group: exclusively or mostly breast-fed (< 6 ounces of formula/24 hours at 6-9 weeks of delivery) for at least 4-6 months Exclusion Criteria: - Currently lactating or lactation within the past 1 month at the time of the screening visit - Diagnosis of diabetes (T1D or T2D) prior to pregnancy - Current use of any glucose-lowering agents - Pregnancy related medical problems including preeclampsia - Major congenital fetal anomalies - Creatinine > 1.5mg/dL, Hematocrit < 35%, ALT and AST > 2.5X upper limit of normal - Known psychiatric disorders, alcohol abuse, HIV, hepatitis, renal disease, hepatic disease, untreated heart disease, untreated thyroid disease, active systemic infection or malignancy - Illicit drug use (by the participant's self-report) - History of post-partum depression - Use of weight loss supplements or dieting 6 months prior to study - Corticosteroid or opiate use within 6 months of study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Hyperinsulinemic-euglycemic clamp
After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ~90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.

Locations

Country Name City State
United States Yale University School of Medicine New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Whole Body Insulin Sensitivity Measured by the Glucose Infusion Rate The glucose infusion rate is determined by the amount of 20% dextrose given during the hyperinsulinemic-euglycemic clamp study, necessary to keep blood glucose levels at the target range (90-100 mg/dL). Higher rates of infused dextrose indicates greater sensitivity to infused insulin during the hyperinsulinemic-euglycemic clamp. Women with gestational diabetes are expected to be insulin resistant. 2 hours and 4 hours
Primary Endogenous Glucose Production Determined with [6,6-2H] Glucose tracer given during the hyperinsulinemic-euglycemic clamp study. Lower values of endogenous glucose production indicates greater hepatic insulin sensitivity. 4 hours
Primary Whole Body Lipid Turnover Rates Determined with [2H5] Glycerol tracer given during the hyperinsulinemic-euglycemic clamp study. Tracer levels in the plasma determinates how the body uses fat in the blood during the hyperinsulinemic-euglycemic clamp study. 4 hours
Secondary Plasma NEFA Measurement of non-esterified fatty acids levels in the plasma at fasting and during the hyperinsulinemic-euglycemic clamp study. NEFA levels in the plasma are higher in individuals less sensitive to the effects of insulin. 4 hours
Secondary Triglycerides Measurement of triglycerides levels in the plasma at fasting and during the hyperinsulinemic-euglycemic clamp study. Triglycerides levels in the plasma are higher in individuals less sensitive to the effects of insulin and with type 2 diabetes. 4 hours
Secondary Insulin Levels Measurement of insulin levels in the plasma at fasting and during the hyperinsulinemic-euglycemic clamp study. Insulin levels in the plasma are higher in insulin resistant individuals. 4 hours
See also
  Status Clinical Trial Phase
Completed NCT02542527 - Evaluation of the Functionality of a Fluid Filled Single Breast Pump N/A
Terminated NCT02755194 - "Drugs in Lactation" Analysis Consortium
Terminated NCT00851591 - Effect of Fenugreek on Milk Production N/A
Withdrawn NCT00181649 - Recombinant Human Prolactin for Lactation Induction Phase 2
Completed NCT00181610 - Recombinant Human Prolactin for Lactation Induction Phase 2
Completed NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Terminated NCT02378233 - Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant N/A
Recruiting NCT06203444 - An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females Phase 1
Completed NCT01747668 - Lactation Fortification Study Phase 3
Completed NCT02621827 - Vitamin D Half-life in Pregnancy and Lactation N/A
Completed NCT01463202 - Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression Phase 4
Completed NCT04593719 - Effect of Lactation Management Model on Breastfeeding Process N/A
Completed NCT01548313 - The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota
Completed NCT02690675 - Iron Supplement Effect on Child Development N/A
Completed NCT05123183 - Nonpharmacological Methods and Lactation N/A
Completed NCT03091985 - Influence of the Brownie Breast Shield on the Dynamics of Milk Removal N/A
Completed NCT02190448 - Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation N/A
Not yet recruiting NCT06264349 - Women and Maternity: Development of a Nutritional Education Project N/A
Recruiting NCT02384655 - Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content Phase 1/Phase 2
Completed NCT02662517 - Growth Hormones and Cells in Human Milk Depending on Gestational Age